Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Illumina: Teva Pharmaceutical Exclusive Distributor of Verifi Test in Israel

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/01/2013 | 01:27pm CET
   By Melodie Warner 
 

Illumina Inc. (>> Illumina, Inc.) said Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)) will be the exclusive distributor of the verifi prenatal test in Israel under a five-year agreement.

Financial terms weren't disclosed.

Illumina paid $350 million in February to buy Verinata Health Inc., which gave it access to Verinata's verifi prenatal test, the broadest non-invasive prenatal test currently available for high-risk pregnancies.

The company said the MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality.

The MOR Institute will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Illumina said the patient registry developed through this collaboration will be the largest and most extensive of its kind.

Illumina shares closed Friday at $74.84 and were inactive premarket. The stock is up 35% this year.

Write to Melodie Warner at melodie.warner@dowjones.com

Stocks mentioned in the article : Illumina, Inc., Teva Pharmaceutical Industries Ltd (ADR)
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
01/20 TEVA PHARMACEUTICAL INDUSTRIES : Receives FDA Approval for VANTRELATM ER (Hydroc..
01/20 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : (TEVA) Position Maintained by Shelter Mut..
01/19 TEVA PHARMACEUTICAL INDUSTRIES LTD ( : TEVA) Secures FDA Approval For Vantreal E..
01/18 TEVA PHARMACEUTICAL INDUSTRIES : Receives FDA Approval for VANTRELATM ER (Hydroc..
01/13 ELI LILLY AND : Teva Loses Alimta Appeal Against Eli Lilly
01/12 TEVA PHARMACEUTICAL INDUSTRIES : GPM Reminds Investors of the January 5 Deadline..
01/12 JANUARY 5 DEADLINE ALERT : Law Offices of Howard G. Smith Reminds Teva Pharmaceu..
01/12 TEVA PHARMACEUTICAL INDUSTRIES : Announces Completion of Sale of UK and Ireland ..
01/12 TEVA PHARMACEUTICAL INDUSTRIES : to Host 2017 Business Outlook Conference Call a..
01/12 TEVA PHARMACEUTICAL INDUSTRIES : Reaches Settlement with Government on FCPA
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/20 UPCOMING EVENTS : Copaxone Patent Decision And Catabasis Muscular Dystrophy Bid
01/20 Teva's Got Potential - And The Complexity To Go With It
01/20 Would You Buy Secretive Taro Pharmaceutical Based On The Track Record Of Indi..
01/20 JPMorgan trims views on Teva and Endo; shares steady premarket
01/20 TEVA PHARMA : Your Brief On The Big Earnings Report Coming In February
Advertisement
Financials ($)
Sales 2016 22 268 M
EBIT 2016 7 157 M
Net income 2016 -
Debt 2016 25 921 M
Yield 2016 3,35%
P/E ratio 2016 6,43
P/E ratio 2017 7,28
EV / Sales 2016 2,68x
EV / Sales 2017 2,27x
Capitalization 33 728 M
More Financials
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 56,2 $
Spread / Average Target 69%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Erez Vigodman President, Chief Executive Officer & Director
Yitzhak Peterburg Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL IN..-8.60%34 211
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.0.39%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results